Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB763 in NASH Chinese Phase II Trial
CTR20180624Phase 2Suspended
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nidufexor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Novartis. Started May 2018; status: suspended.
02
Drugs
nidufexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20180624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180624.